-
公开(公告)号：US20240350593A1
公开(公告)日：2024-10-24
申请号：US18621336
申请日：2024-03-29
申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , SORBONNE UNIVERSITE , UNIVERSITÉ PARIS CITÉ , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
IPC分类号： A61K38/38 , A61K38/01 , A61K47/36 , A61P27/02 , A61K31/573
CPC分类号： A61K38/38 , A61K38/014 , A61K47/36 , A61P27/02 , A61K31/573
摘要： This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.
-
公开(公告)号：US12110551B2
公开(公告)日：2024-10-08
申请号：US17563107
申请日：2021-12-28
申请人： BIO-RAD EUROPE GMBH , ARIANA PHARMACEUTICALS , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
发明人： Bénédicte Watelet , Tarik Asselah , Ivan Bieche , Isabelle Catherine Batxelli , Nathalie Jullian , Michel Vidaud , Patrick Marcellin , Daniel Laune , Mohammad Afshar , Eve Mathieu Dupas
IPC分类号： C12Q1/68 , C12Q1/6876 , C12Q1/6883 , G01N33/576 , C12Q1/70
CPC分类号： C12Q1/6876 , C12Q1/6883 , G01N33/576 , C12Q1/706 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , G01N2800/085 , G01N2800/60 , G01N2800/7052
摘要： The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:
SPP1, and
at least one gene from among A2M and VIM, and
at least one gene from among IL8, CXCL10 and ENG, and
optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.-
公开(公告)号：US20240197821A1
公开(公告)日：2024-06-20
申请号：US18495355
申请日：2023-10-26
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS , INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) , Université Paris-Sud
发明人： Joël DORE , Jamila FAIVRE , Nicolas MONIAUX , Christian BRECHOT , Marion DARNAUD
CPC分类号： A61K38/1709 , A23L33/19
摘要： The present disclosure concerns a Reg3α polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for protecting oxygen sensitive gram-positive bacteria, compositions including the polypeptide, and their use. The disclosure shows that increasing concentration of the hReg3α lectin into the gastrointestinal tract (GIT) lumen of hReg3α-transgenic mice induced significant changes in composition of gut microbiota, and dramatically improved host resistance to intestinal inflammation. The Reg3α polypeptide may be used for preventing or treating microbiota-related diseases and/or disorders, including inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders, and the prevention and treatment methods may also include transferring to said patient fecal microbiota from a human or animal expressing the Reg3α polypeptide.
-
公开(公告)号：US20240147985A1
公开(公告)日：2024-05-09
申请号：US18410112
申请日：2024-01-11
申请人： UNIVERSITE DE TECHNOLOGIE DE COMPIEGNE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , SORBONNE UNIVERSITE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
IPC分类号： A01N1/02
CPC分类号： A01N1/0247
摘要： Disclosed is a device for the perfusion of an organ, including: a container of fluid, containing an organ bathed in the perfusion fluid; a first path including an inlet, an outlet and a pump; and a second path including an inlet, an outlet and a pump. The “arterial” outlet of the first path has a diameter smaller than a diameter of the “portal” outlet of the second path. The device additionally includes, between the pump and the outlet of the first path and/or between the pump and the outlet of the second path, an oxygenation unit arranged to oxygenate the fluid emerging from the “arterial” outlet of the first path more than the fluid emerging from the “portal” outlet of the second path. The device can include a communication path between the first path and the second path in order to oxygenate the second path. Use in liver transplantation.
-
公开(公告)号：US20240090774A1
公开(公告)日：2024-03-21
申请号：US18262953
申请日：2022-01-25
申请人： OCTOGONE MEDICAL , UNIVERSITE PARIS CITE , INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
发明人： Emmanuel MESSAS , Frédéric SALDMANN
CPC分类号： A61B5/02007 , A61B5/0015 , A61B5/053 , A61B5/6833 , A61B5/6867 , A61B5/7267 , A61B5/7275 , A61B2560/045 , A61B2560/0462 , A61B2562/0204 , A61B2562/0219 , A61B2562/0271
摘要： System (1) for predicting an at least partial rupture or the detachment of a vascular plaque which could lead to a stroke or for analysing the biomechanical properties of the wall of an internal jugular vein in order to predict a risk of thrombosis, comprising: a monitoring device (2) comprising a temperature sensor (5) configured to measure the temperature of the vascular plaque or the wall of the jugular vein, a vibration sensor (4) configured to measure mechanical waves passing through the vascular plaque and the underlying walls, a motion sensor (6) configured to measure the movements of the plaque or the wall of the jugular vein (6), an electrical sensor configured to measure a parameter related to the electrical impedance of the plaque, an acoustic wave sensor and a calculation unit (10) configured to analyse the data from the monitoring device (2) by artificial intelligence.
-
公开(公告)号：US11903382B2
公开(公告)日：2024-02-20
申请号：US18095943
申请日：2023-01-11
申请人： UNIVERSITE DE TECHNOLOGIE DE COMPIEGNE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , SORBONNE UNIVERSITE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
CPC分类号： A01N1/0247
摘要： Disclosed is a device for the perfusion of an organ, including: a container of fluid, containing an organ bathed in the perfusion fluid; a first path including an inlet, an outlet and a pump; and a second path including an inlet, an outlet and a pump. The “arterial” outlet of the first path has a diameter smaller than a diameter of the “portal” outlet of the second path. The device additionally includes, between the pump and the outlet of the first path and/or between the pump and the outlet of the second path, an oxygenation unit arranged to oxygenate the fluid emerging from the “arterial” outlet of the first path more than the fluid emerging from the “portal” outlet of the second path. The device can include a communication path between the first path and the second path in order to oxygenate the second path. Use in liver transplantation.
-
7.发明公开公开(公告)号：US20240050390A1
公开(公告)日：2024-02-15
申请号：US18266499
申请日：2021-12-10
IPC分类号： A61K31/201 , A61K33/18 , A61K36/66 , A61K9/107
CPC分类号： A61K31/201 , A61K33/18 , A61K36/66 , A61K9/1075
摘要： The present invention relates to an embolizing emulsion comprising iodinated oil and an aqueous phase comprising a water-soluble contrast agent for use in the treatment of inflammatory hypervascularization associated with a musculoskeletal disorder.
-
公开(公告)号：US20230416344A1
公开(公告)日：2023-12-28
申请号：US17918863
申请日：2021-04-16
申请人： Alexion Pharmaceuticals, Inc. , Assistance Publique, Hopitaux de Paris , Djillali Annane , Veronique Fremeaux-Bacchi , Regis Peffault De Latour
发明人： Sharon Barr , Derek Dunn , Xiang Gao , Shamsah D. Kazani , Michele Mercuri , Jonathan Monteleone , Stephan Ortiz , Scott T. Rottinghaus , Martine Zimmermann , Djillali Annane , Veronique Fremeaux-Bacchi , Regis Peffault De Latour
IPC分类号： C07K16/18 , A61K45/06 , A61P31/14 , G01N33/569
CPC分类号： C07K16/18 , A61K45/06 , A61P31/14 , G01N2469/20 , C07K2317/76 , C07K2317/24 , G01N33/56983
摘要： The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by a virus, e.g., corona virus; Dengue virus (DENY); Ross River vims (RRV) and/or influenza virus (flu) by administering an effective amount of a complement modulator, such as, e.g., C5 inhibitor, such as eculizumab or an eculizumab variant or a C5a inhibitor such as olendalizumab (ALXN1007) or a variant thereof, to the subject. In addition, the present disclosure relates to, inter alia, a method of treating human patients inflicted with severe coronavirus disease-2019 (severe COVID-19) who is undergoing treatment with eculizumab. The method includes measuring a level of circulating component C5b-9 (membrane attack complex), in the patient's blood sample to titrate an effective eculizumab dose for the treatment of COVID-19.
-
公开(公告)号：US11849958B2
公开(公告)日：2023-12-26
申请号：US16979999
申请日：2019-03-13
CPC分类号： A61B17/1739 , A61B8/4477 , A61B34/20 , A61B90/10 , A61N7/00 , A61B2090/103 , A61N2007/0026
摘要： The present invention relates to a surgical kit for use in a craniectomy procedure, the surgical kit comprising: a medical device to be implanted in a cranial bone of a patient, the medical device (10) including several transducers for emitting ultrasound waves for treatment of brain tissue, a surgical accessory (20) intended to be positioned on the cranial bone of the patient, the surgical accessory (20) including a body whose outer perimeter defines the dimensions of an opening that is to be made in the cranial bone of the patient in order to receive the medical device, characterized in that the surgical accessory (20) comprises a plurality of holes (201) formed in the body, the position of each hole (201) on the body coinciding with the position of the axis of symmetry of a respective transducer, such that the accessory is able to be positioned optimally through the joint use of a neuronavigation system.
-
公开(公告)号：US20230285381A1
公开(公告)日：2023-09-14
申请号：US18296543
申请日：2023-04-06
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ PARIS-SACLAY , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP) , HOPITAL MARIE LANNELONGUE
发明人： Sylvia COHEN-KAMINSKY , Marc HUMBERT , Sebastien DUMAS , Gilles BRU-MERCIER , Samir MESSAOUDI , Jean-Daniel BRION , Mouad ALAMI , Gilles GALVANI
IPC分类号： A61K31/46 , A61P9/12 , A61K45/06 , C07D451/00 , C07D451/02
CPC分类号： A61K31/46 , A61K45/06 , A61P9/12 , C07D451/00 , C07D451/02
摘要： The present invention relates to compounds of formula (I);
for use as peripheral NMDA receptor antagonists.
-
-
-
-
-
-
-
-
-
搜索结果
554 条记录 (耗时 0.051 秒)
